USFDA concludes cGMP audit at Cohance Lifesciences’ API manufacturing plant
The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero observations
Cohance Lifesciences, formerly Suven Pharmaceuticals has announced completion of a general current Good Manufacturing Practices (cGMP) audit by USFDA at its API manufacturing facility in Jaggaiahpet, Andhra Pradesh.
The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations, the company said.
In its statement, the company further added, “We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.”